MedTrace Logo

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

NCT04268394 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-08-18

No results posted yet for this study

Summary

It is a phase 1, open-label, single-center, three-part study to assess the safety, tolerability, and pharmacokinetics of multiple doses of CC-99677 administered alone or in combination with either methotrexate and sulfasalazine; itraconazole, rifampin, midazolam, or a cocktail of digoxin, metformin, and rosuvastatin in healthy subjects

Conditions

  • Healthy Volunteer

Interventions

DRUG

CC-99677

CC-99677

DRUG

Methotrexate

Methotrexate

DRUG

Sulfasalazine

Sulfasalazine

DRUG

Itraconazole

Itraconazole

DRUG

Rifampin

Rifampin

DRUG

Midazolam

Midazolam

DRUG

Digoxin

Digoxin

DRUG

Metformin

Metformin

DRUG

Rosuvastatin

Rosuvastatin

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Kofi Mensah, MD, PhD · Celgene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-13
Primary Completion
2021-06-02
Completion
2021-06-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268394 on ClinicalTrials.gov